TY - JOUR
T1 - Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529)
T2 - A Systematic Review with Meta-Analysis and Meta-Regression
AU - Pratama, Nando Reza
AU - Wafa, Ifan Ali
AU - Budi, David Setyo
AU - Sutanto, Henry
AU - Asmarawati, Tri Pudy
AU - Barlian Effendi, Gema
AU - Wungu, Citrawati Dyah Kencono
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/12
Y1 - 2022/12
N2 - Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE over time. Compared to full dose, booster dose of overall vaccines provided better protection against any and severe Omicron infections within 3 months (p < 0.001), and within 3 months or more in any, severe, and symptomatic infections (p < 0.001). From meta-regression analysis of overall vaccines, the full-dose VE against any and symptomatic Omicron infections reduced per month by 2.45% and 5.5%, respectively; whereas booster dose effectiveness against any and symptomatic Omicron infections reduced per month by 1.79% and 1.14%, respectively. The VE estimates of booster dose provide excellent protection against symptomatic infection compared to full dose. The VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 against Omicron infection are generally moderate, despite the VE estimates declining over time.
AB - Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE over time. Compared to full dose, booster dose of overall vaccines provided better protection against any and severe Omicron infections within 3 months (p < 0.001), and within 3 months or more in any, severe, and symptomatic infections (p < 0.001). From meta-regression analysis of overall vaccines, the full-dose VE against any and symptomatic Omicron infections reduced per month by 2.45% and 5.5%, respectively; whereas booster dose effectiveness against any and symptomatic Omicron infections reduced per month by 1.79% and 1.14%, respectively. The VE estimates of booster dose provide excellent protection against symptomatic infection compared to full dose. The VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 against Omicron infection are generally moderate, despite the VE estimates declining over time.
KW - COVID-19
KW - Omicron variant
KW - SARS-CoV-2
KW - booster vaccination
KW - vaccine effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85144701104&partnerID=8YFLogxK
U2 - 10.3390/vaccines10122180
DO - 10.3390/vaccines10122180
M3 - Review article
AN - SCOPUS:85144701104
SN - 2076-393X
VL - 10
JO - Vaccines
JF - Vaccines
IS - 12
M1 - 2180
ER -
